


NIMBLE Diagnostics

“Pioneering Implant Care”

Oriol Iborra, CEO
Cuatrecasas Acelera – Demo Day

Stents are one of the **Most Implanted** devices in the world



50 M people has a stent
+ **4M** people accumulates each year

70% Cardiovascular

(Heart attacks, heart failure...)

10% Cerebrovascular

(Stroke, aneurysms...)

10% Peripheral

(Femoral, carotid....)


10% Other

(Pulmonar, renal....)


Stents can become **Blocked** or **Damaged**

30%


Of stents will develop a
problem in the first 2 years
post-implantation



In-stent restenosis (ISR)



Stent thrombosis (ST)



Stent fractures (SF)

The standard of care is **Complex, Expensive** and **Invasive**

Catheter Angiography



Anesthesia/
Sedation



X-Ray
(patient and clinician)



72h
Hospitalization

Increased preventable problems



Heart attack



Stroke



Sudden Death

The WAEVE[®] System


First **non-invasive**, microwave-based technology for stent monitoring

Step 1: Put both antennas touching the skin near the stent.

Our system will indicate if the antennas are corecctly positioned.

Step 2: Click play and wait for 5 seconds

Our system will indicate when the measurement has ended.



The WAEVE[®] System

Revolutionize patient management **independent of the stent's type or location**



Strong IP strategy

- ✓ Positive FTO
- ✓ 1 patent granted (WO/2019/057685)
- ✓ 1 patent submitted (EP24382920)
- ✓ 1 patent in drafting stages
- ✓ Algorithms registered
- ✓ Trademarks granted

Fantastic results so far


Pre-clinical validation with **100% sensitivity** and **90% specificity**



First-in-Human study completed



11 patients



Clinical Data

FiH completed; n=11 patients




100% diagnostic classification according to clinical guidelines & **strong concordance with OCT & Angiography** results for ISR grading

The outpatient measurement lasted less than 5 minutes per patient. 90% of patients <50% ISR. 1 Type IV fracture identified.




11 patients

- ◆ P001 ■ P002 ▲ P003 ✕ P004 ✱ P005 ● P006
- ⊕ P008 — P009 — P010 ◆ P013 ■ P015



Patient P005. Weight 66kg. Target segment lumen area 4.78mm². Xience Alpine drug eluting stent (Abbott). ISR 17% by OCT



Patient P005. Time-domain electromagnetic signal. Post-processed ISR 20%.

Paradigm shift for patients with implanted stents

1. Stent Implantation




SAFE patient discharge

2. Stent Diagnosis




Substitute invasive diagnostics

3. Monitoring – Follow Up




Pipeline company with a total potential market of over **90B€**

Target Market 2028
Coronary stents **8B€**




Near-Term TAM

Target Market 2032
Medical implants **41B€**



Mid-Term TAM

Total Markets 2040
All potential markets: **90B€**




Long-Term TAM

- Cardiovascular stent
- Other stents (neurovascular, renal, pulmonar)
- Prosthetic implants
- Valves and sensors

- Clinical
- Industrial
- Veterinary
- At home device
- Software App

Highly scalable commercialization strategy



Clients



Budgetary Impact



Early diagnosis of stent-related problems avoiding severe outcomes (**25% of heart attacks, 37% of hospitalizations** and **65% of premature deaths**).



Avoid non-productive procedures



Optimization of drug spending and reduction of AEs

**Direct potential savings to the
healthcare system**

1.6M€/year/Hospital



sermo

Early HTA and WTP external validation

Our Leadership Team: Guiding a 10+ member company



Oriol Iborra, PhD
CEO & co-founder
 PhD in cardiology, scientist and entrepreneur



Susana Amorós, MSe
CTO & co-founder
 Telecommunications eng., microwaves expert



Oriol Rodríguez, MD
CMO & co-founder
 +20y in interventional cardiology



Carol Gálvez, PhD
CSO & co-founder
 Expert in pre-clinical animal models in cardiology



Andrés Ortega, MSc
COO
 +15y in global marketing and sales



Naia Jiménez, MSc
BD Manager
 +5y in private and public fundraising, and mkt access



Pol Gómez, BSc
Clinical Opt. Manager
 +7y in mgmt of clinical studies in cardiology



Ana Pérez, MSc
QA/RA Manager
 +10y in regulatory affairs of medical products



Supported by key experts



Prof. Bayés Genís, MD, PhD
Co-founder
 Global Cardiovascular KOL



Yolanda Casas, MBA
Business Advisor – Medical Devices
 +15 years in the field of Medical Devices and Automation solutions



Prof. O’Callaghan, PhD
Co-founder & board member
 European microwave KOL



Prof. Peter Fitzgerald, MD, PhD
Medical & Business Advisor – Cardiology MedDev
 Serial entrepreneur, 14 start-up sold, >175 clinical trials led



Prof. Tejada Palacios, PhD
Co-founder
 Global physics KOL




Horst Siever, MD, PhD
Medical Advisor – Interventional cardiology
 Director CardioVascular Center Frankfurt

Public Funding

Private Funding

Acceleration

NIMBLE Roadmap



Series A 12M€


Looking for 1 Lead Investor 3-5M€

Milestones:

- Pivotal trial EU (multicentric)
- CE mark
- Development of new applications
- Start commercialization

5.5M€ raised to date

Use of funds



■ G&A ■ R&D ■ Market Access ■ Clinical Trial

Programa Cuatrecasas Acelera



Identification of Needs

- IPR Strategy
- Regulatory and Quality Strategy
- Data Processing and Analysis in Research
- Team and Employment Contracts
- Private Fundraising and Valuation



Progress

- NDA and contracts with providers
- Annex to **employment contracts**: IP agreements
- **GDPR** compliance (EU 2016/679); **AI** compliance (EU 2024/1689); **NIS2** compliance; and future applicable regulations
- **Virtual Data Room** reviewed and improved
- **Series A** Strategy defined + suitable conditions



Help us make painless, easy-to-use, fast and accessible stent diagnostics

Dr. Oriol Iborra, CEO
oriol.iborra@dxnimble.com